Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Portfolio Pulse from dijoy@benzinga.com
Mineralys Therapeutics (NASDAQ:MLYS) reported a Q4 EPS loss of $(0.61), surpassing the analyst consensus estimate of $(0.82) by 25.61%. This marks a 64.94% improvement over the $(1.74) per share loss from the same period last year.
March 21, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mineralys Therapeutics reported a smaller than expected Q4 EPS loss, showing significant improvement over the previous year.
Beating EPS estimates typically generates positive investor sentiment, suggesting an optimistic outlook for MLYS. The significant year-over-year improvement further strengthens the case for potential short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100